Why Are Recently Published Platelet Counts in Normal Mice So Low?
To the Editor:
Unusually low platelet counts were reported for control, untreated mice in two recent publications in Blood" In neither case was the discrepancy between the reported platelet counts and those traditionally found noted or explained. Our experience' and that of others4 with platelet counts in blood from mice of several strains and different ages is that average values for groups of normal mice are almost invariably greater than 1,000,000 plateletdpl of blood. This value is obtained when phase contrast microscopys or automated counting in platelet-rich plasma6 is used to count the platelets. We believe it is unlikely that strain, age, or sex of the mice accounted for the marked differences between the higher values usually detected and the ones reported in the recent publications.'*2 We think that the likely explanation for the differences lies in methods used to collect blood andor count platelets, and we respectfully request that the investigators respond to the comments below.
Longmore et all counted platelets in orbital plexus blood collected from 6-week-old female NIWSwiss mice by using a Serono-Baker 9000 Cell Counter. Average values of 450,000 to 470,OOO/pL were reported for untreated mice in Table 1 . They noted that platelet clumping was excluded by ''concurrent examination of blood smears," thus eliminating one source of error in automated platelet counts. However, we would also l i e to know what measures were taken to ensure that the automated cell counter accurately counted the entire population of mouse platelets. This is essential, because murine platelets are substantially smaller than the human platelets' for which automated counters are typically calibrated. In at least three other reports, the Serono-Baker 9OOO was used to count murine platelets.'"' Control values varied from a low of 798,000'' to a high of 965,000,9 all higher than in the report under question,' but nonetheless lower than usual. Our own unpublished experience, separately obtained, is that counting murine platelets with automated cell counters can be problematic.
Harrison et alz counted platelets "by routine methods" in female C57B1/6J X DBAL? F1-specific pathogen-free mice greater than 8 to 12 weeks of age. The average value for their controls was only 200,000 PlateletdpL. In this case, it is also important to know the For personal use only. on August 30, 2017. by guest www.bloodjournal.org From methods that were used to collect blood and count platelets and the quality controls that were applied to determine if the apparent thrombocytopenia was real or artifactual. They found that administration of AZT resulted in a worsening of the thrombocytopenia.
This contrasts with the report of Chow et al . " who found that administration of a similar dose of AZT for a similar length of time to female C57B1/6 mice of 6 to 8 weeks of age produced thrombocytosis. Chow et a l l ' also used an automated cell counter (ELT-8) without a statement about its calibration for murine platelets, and their control platelet counts (988,OOO/pL) were also low by traditional standards. Because of the variability in control values, one cannot know which, if either, of the results with AZT is correct. However, analysis of the effects of AZT on megakaryocytopoiesis in mice" and on platelet production in human beings" suggests that platelet production is stimulated by M T .
Clearly, it is advantageous to be able to quickly count murine platelets in samples of whole blood with automated cell counters. However, machines will essentially always produce a number whether it is the same as the actual platelet count or not. The variability in platelet counts in the reports cited and the uniform tendency with a retrovirus expressing an oncogenic erythropoietin receptor. 
Response
Levin and Ebbe point out that the platelet counts in control, nor-3 pm (volume, 0.5 to 14 pm3), it is possible that, with the window mal, adult mice reported in our study were unusually low, and sugsettings used, small platelets may not have been counted on the gest that possible explanations lie in the methods of blood collection automated counter. However, both manual and automated methods and platelet counting. In control mice, as well as experimental mice, gave essentially the same result, with the manual count being slightly 200 pL of blood was collected from the orbital plexus into tubes lower and exhibiting a greater standard deviation, thus having a containing 10 pL of EDTA. Whole blood, not platelet-rich plasma, higher likelihood of observer error. was usedfor the determination of platelet numbers. Thus, the minor dilution effect of 1/20 was not taken into account. This adjustment would not significantly change the reported values. Platelets were counted using a Serono-Baker 9OOO Cell counter with a volume window setting of 1.8 to 20.2 pm'. Concurrently, blood smears were examined to exclude platelet clumping and platelet counts were manually determined. Assuming a mouse platelet diameter of 1 to were processed in an identical manner and run on the same machine to obtain results that were internally consistent. The machine was indeed calibrated for routine clinical specimens,'.' and the explanation for the discrepancies between our values and those reported for other strains of mice may be caused by the gating calibration of the Coulter machine used in our study. At the time of the experiments, selected specimens were obtained by directly drawing tail vein blood into capillary tubes. The hematocrits determined by centrifugation were consistent with the Coulter readings; however, manual platelet counts were not performed?
The literature regarding the effects of AZT on megakaryopoiesis in mice yields conflicting findings. Gallicchio AZT remains an important agent in the management of HIVinfected patients; our findings confirm other experimental models that show that erythropoietin is effective in ameliorating the hematopoietic toxicity of AZT, and demonstrate that heme potentiates the action of erythropoietin on hematopoiesis. It is our hope that clinical investigation of the use of heme in combination with erythropoietin will continue. Heme arginate has been shown to cause elevation of platelet and red blood cell counts in patients with myelodysplastic syndrome~,8~ and it may be that the Combination of heme and erythropoietin will be beneficial to HIV-infected patients receiving AZT 
